Paul J. Mellett

Senior Vice President, Chief Financial & Administration Officer at Enanta Pharmaceuticals, Inc.

Paul J. Mellett

Paul J. Mellett

Senior Vice President, Chief Financial & Administration Officer at Enanta Pharmaceuticals, Inc.

Overview
Career Highlights

Enanta Pharmaceuticals, Inc.
Essential Therapeutics, Inc
GelTex Pharmaceuticals, Inc.

RelSci Relationships

1944

Number of Boards

1

Birthday

1956

Age

64

Contact Data
Trying to get in touch with Paul J. Mellett? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Paul J. Mellett likely has professional access to. A relationship does not necessarily indicate a personal connection.

President, Chief Executive Officer & Director at Enanta Pharmaceuticals, Inc.

Relationship likelihood: Strong

Venture Partner at RA Capital Management LLC

Relationship likelihood: Strong

Senior Vice President & General Counsel at Enanta Pharmaceuticals, Inc.

Relationship likelihood: Strong

Senior Vice President, Research & Development & Chief Scientific Officer at Enanta Pharmaceuticals, Inc.

Relationship likelihood: Strong

Founder at LifeMine Therapeutics, Inc.

Relationship likelihood: Strong

Senior Vice President, Chief Medical Officer at Enanta Pharmaceuticals, Inc.

Relationship likelihood: Strong

Executive Officer at Dance Biopharm Holdings, Inc.

Relationship likelihood: Strong

Former Strategic Advisor at Access BridgeGap Ventures

Relationship likelihood: Strong

Director, Investor Relations at Enanta Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chairman & Chief Executive Officer at Fenway Pharmaceuticals, Inc.

Relationship likelihood: Strong

Paths to Paul J. Mellett
Potential Connections via
Relationship Science
You
Paul J. Mellett
Senior Vice President, Chief Financial & Administration Officer at Enanta Pharmaceuticals, Inc.
Education
BS in Business Administration
Class of 1977

Boston College is one of the nation's best and most selective universities, with U.S. News & World Report ranking Boston College 31st among national universities, and Forbes ranking it 26th in its 2012 America's Best Colleges listing. Boston College confers more than 4,000 degrees annually in more than 50 fields of study through eight schools and colleges. Faculty members are committed to both teaching and research having earned nearly $60 million in research grants in the last year alone. The University has made a major commitment to academic excellence. As part of its Strategic Plan, Boston College is in the process of adding 100 new faculty positions, expanding faculty and graduate research, increasing student financial aid to more than $128 million annually, and widening opportunities in key undergraduate programs, such as international study, internships and student formation. Boston College has experienced tremendous growth in recent years, including a 75 percent increase in undergraduate applications over the past decade, to more than 34,000 for the 2,250 seats in its freshman class. During the same period, an increase in voluntary giving from alumni has helped to move the University's endowment to approximately $1.9 billion. Boston College students have also earned more than 200 prestigious academic scholarships over the past decade, including 2 Rhodes Scholarships, 4 Marshalls, 9 Goldwaters and 162 Fulbright grants.

Career History
Senior Vice President, Chief Financial & Administration Officer
2003 - Current

Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Chief Financial Officer & Senior Vice President
2001 - 2003

Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections

Chief Financial Officer & Vice President-Administration
1997 - 2000

GelTex Pharmaceuticals, Inc. was developed non-absorbed, polymer-based pharmaceuticals that selectively bind and eliminate target substances from the intestinal tract. The company is a subsidiary of Geltex Corp. GelTex Pharmaceuticals was founded by Henry E Blair & James B Tananbaum in 1991 and was located in Waltham, MA.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Paul J. Mellett. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Paul J. Mellett's profile does not indicate a business or promotional relationship of any kind between RelSci and Paul J. Mellett.